東華大學圖書館 |

語系: 繁體中文

說明(常見問題)

回圖書館首頁

手機版館藏查詢

登入

回首頁

切換: 標籤 | MARC模式 | ISBD

An Investigation of Anergy As a Pote...

Grossman, Mark Alexander.

FindBook

Google Book

Amazon

博客來

An Investigation of Anergy As a Potential Mechanism of Human Immunodeficiency Virus Type 1 Escape from Control by Cytotoxic T Lymphocytes.

紀錄類型:	書目-電子資源 : Monograph/item
正題名/作者:	An Investigation of Anergy As a Potential Mechanism of Human Immunodeficiency Virus Type 1 Escape from Control by Cytotoxic T Lymphocytes./
作者:	Grossman, Mark Alexander.
出版者:	Ann Arbor : ProQuest Dissertations & Theses, : 2019,
面頁冊數:	107 p.
附註:	Source: Dissertations Abstracts International, Volume: 80-10, Section: B.
Contained By:	Dissertations Abstracts International80-10B.
標題:	Public health. -
電子資源:	http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=13810858
ISBN:	9781392017005

An Investigation of Anergy As a Potential Mechanism of Human Immunodeficiency Virus Type 1 Escape from Control by Cytotoxic T Lymphocytes.
Grossman, Mark Alexander.

An Investigation of Anergy As a Potential Mechanism of Human Immunodeficiency Virus Type 1 Escape from Control by Cytotoxic T Lymphocytes. - Ann Arbor : ProQuest Dissertations & Theses, 2019 - 107 p.

Source: Dissertations Abstracts International, Volume: 80-10, Section: B.

Thesis (Ph.D.)--University of California, Los Angeles, 2019.

This item must not be sold to any third party vendors.

CD8+ cytotoxic T lymphocytes (CTL) play an important role in HIV-1 infection. However, in most persons the HIV-1-specific CTL become dysfunctional. It has been suggested that anergy, a mechanism of T cell tolerance, may play a role in HIV-1-specific CTL dysfunction. Since HIV-1 is known to escape CTL recognition through mutation of epitopes to produce weak agonist altered peptide ligands (APL)-and anergy is thought to occur through suboptimal recognition-we hypothesized that weakly-recognized epitope variants may suboptimally stimulate the T-cell receptor (TCR) and trigger aberrant TCR signaling, leading to CTL anergy and enhanced viral persistence. We investigated weak agonist APL-mediated anergy as a potential mechanism of dysfunction in three HIV-1-specific CTL clones targeting three different epitopes. Clones were exposed to weakly-recognized epitope variants and screened for cytokine secretion, gene expression of markers of anergy and other forms of T cell dysfunction, and subsequent capacity to kill index peptide-presenting target cells in secondary challenge. Under those conditions, although suboptimal stimulation dampened cytokine secretion, we observed no patterns in gene expression profile consistent with anergy. Additionally, pre-exposure of CTL to weak agonist epitope variants had no discernable effect on their subsequent capacity to kill index epitope-bearing target cells. These data suggest that while weak agonist epitope variants evade CTL pressure through reduced recognition, their weak agonism does not appear to drive dysfunction of HIV-1-specific CTL, arguing against a role of APL-induced anergy in HIV-1-specific CTL dysfunction. However, under different experimental conditions, one HIV-1-specific CTL clone appeared to demonstrate varying degrees of reduced recognition of index epitope after pre-treatment with weak agonist APL stimulation. To try to reconcile these seemingly contradictory results, additional literature on the role of costimulation in both anergy and CD28- effector CTL is incorporated into the discussion. In Chapter 7, I propose a speculative model of how HIV-1-derived weak agonist APL, in conjunction with blockade of CD28-independent costimulatory pathways, may be able to cause HIV-1-specific CTL anergy in vivo. In Chapter 8, alternative approaches are suggested for possible future studies to resolve the confounding issues that still surround the field of APL-induced T cell anergy.

ISBN: 9781392017005Subjects--Topical Terms:

534748
Public health.

An Investigation of Anergy As a Potential Mechanism of Human Immunodeficiency Virus Type 1 Escape from Control by Cytotoxic T Lymphocytes.
LDR:03642nmm a2200349 4500 001 2210747
005 20191121124306.5
008 201008s2019 ||||||||||||||||| ||eng d
020 $a 9781392017005
035 $a (MiAaPQ)AAI13810858
035 $a (MiAaPQ)ucla:17603
035 $a AAI13810858
040 $a MiAaPQ $c MiAaPQ
100 1 $a Grossman, Mark Alexander. $3 3437881
245 1 3 $a An Investigation of Anergy As a Potential Mechanism of Human Immunodeficiency Virus Type 1 Escape from Control by Cytotoxic T Lymphocytes.
260 1 $a Ann Arbor : $b ProQuest Dissertations & Theses, $c 2019
300 $a 107 p.
500 $a Source: Dissertations Abstracts International, Volume: 80-10, Section: B.
500 $a Publisher info.: Dissertation/Thesis.
500 $a Advisor: Yang, Otto O.
502 $a Thesis (Ph.D.)--University of California, Los Angeles, 2019.
506 $a This item must not be sold to any third party vendors.
520 $a CD8+ cytotoxic T lymphocytes (CTL) play an important role in HIV-1 infection. However, in most persons the HIV-1-specific CTL become dysfunctional. It has been suggested that anergy, a mechanism of T cell tolerance, may play a role in HIV-1-specific CTL dysfunction. Since HIV-1 is known to escape CTL recognition through mutation of epitopes to produce weak agonist altered peptide ligands (APL)-and anergy is thought to occur through suboptimal recognition-we hypothesized that weakly-recognized epitope variants may suboptimally stimulate the T-cell receptor (TCR) and trigger aberrant TCR signaling, leading to CTL anergy and enhanced viral persistence. We investigated weak agonist APL-mediated anergy as a potential mechanism of dysfunction in three HIV-1-specific CTL clones targeting three different epitopes. Clones were exposed to weakly-recognized epitope variants and screened for cytokine secretion, gene expression of markers of anergy and other forms of T cell dysfunction, and subsequent capacity to kill index peptide-presenting target cells in secondary challenge. Under those conditions, although suboptimal stimulation dampened cytokine secretion, we observed no patterns in gene expression profile consistent with anergy. Additionally, pre-exposure of CTL to weak agonist epitope variants had no discernable effect on their subsequent capacity to kill index epitope-bearing target cells. These data suggest that while weak agonist epitope variants evade CTL pressure through reduced recognition, their weak agonism does not appear to drive dysfunction of HIV-1-specific CTL, arguing against a role of APL-induced anergy in HIV-1-specific CTL dysfunction. However, under different experimental conditions, one HIV-1-specific CTL clone appeared to demonstrate varying degrees of reduced recognition of index epitope after pre-treatment with weak agonist APL stimulation. To try to reconcile these seemingly contradictory results, additional literature on the role of costimulation in both anergy and CD28- effector CTL is incorporated into the discussion. In Chapter 7, I propose a speculative model of how HIV-1-derived weak agonist APL, in conjunction with blockade of CD28-independent costimulatory pathways, may be able to cause HIV-1-specific CTL anergy in vivo. In Chapter 8, alternative approaches are suggested for possible future studies to resolve the confounding issues that still surround the field of APL-induced T cell anergy.
590 $a School code: 0031.
650 4 $a Public health. $3 534748
650 4 $a Physiology. $3 518431
650 4 $a Epidemiology. $3 568544
650 4 $a Immunology. $3 611031
690 $a 0573
690 $a 0719
690 $a 0766
690 $a 0982
710 2 $a University of California, Los Angeles. $b Microbiology, Immunology, and Molecular Genetics. $3 3183000
773 0 $t Dissertations Abstracts International $g 80-10B.
790 $a 0031
791 $a Ph.D.
792 $a 2019
793 $a English
856 4 0 $u http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=13810858